Convergence of biomarkers, bioinformatics and nanotechnology for individualized cancer treatment

• Published in: Trends in biotechnology (Regular ed.) Vol. 27; no. 6; pp. 350 - 358
• Main Authors: Phan, John H, Moffitt, Richard A, Stokes, Todd H, Liu, Jian, Young, Andrew N, Nie, Shuming, Wang, May D
• Format: Journal Article
• Language: English
• Published: Cambridge, MA Elsevier Ltd 01.06.2009; [London]: Elsevier Science; Cell Press; Elsevier Limited
• Subjects: Antineoplastic Protocols; Behavior; Bioinformatics; Biological and medical sciences; Biomarkers; Biomarkers, Tumor; Biotechnology; Cancer; Cancer therapies; Carcinoma, Renal Cell - diagnosis; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - therapy; Computational Biology; Convergence; Data processing; Disease; Disease detection; Fundamental and applied biological sciences. Psychology; Gene expression; Health. Pharmaceutical industry; Humans; Industrial applications and implications. Economical aspects; Internal Medicine; Kidney Neoplasms - diagnosis; Kidney Neoplasms - drug therapy; Kidney Neoplasms - therapy; Kinases; Knowledge Bases; Miscellaneous; Nanoparticles; Nanotechnology; Nanotechnology - methods; Neoplasms - diagnosis; Neoplasms - drug therapy; Neoplasms - therapy; Patients; Polypeptides; Proteins; Quantum dots; Technological change; Tumors; Treatment; Biological marker; Review; Malignant tumor; Personalized medicine; Bioinformatics; Predictive medicine; Nanotechnology; Cancer
• ISSN: 0167-7799; 1879-3096
• DOI: 10.1016/j.tibtech.2009.02.010

Recent advances in biomarker discovery, biocomputing and nanotechnology have raised new opportunities in the emerging fields of personalized medicine (in which disease detection, diagnosis and therapy are tailored to each individual's molecular profile) and predictive medicine (in which genetic and molecular information is used to predict disease development, progression and clinical outcome). Here, we discuss advanced biocomputing tools for cancer biomarker discovery and multiplexed nanoparticle probes for cancer biomarker profiling, in addition to the prospects for and challenges involved in correlating biomolecular signatures with clinical outcome. This bio-nano-info convergence holds great promise for molecular diagnosis and individualized therapy of cancer and other human diseases.